What's in Protagonist Therapeutics, Inc.'s pipeline?

Protagonist Therapeutics, Inc. has 6 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Protagonist Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: Dong-A ST Co., Ltd., Ministry of Health, Malaysia, Sandoz.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/protagonist-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Protagonist Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Protagonist Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Open-label rusfertide	Open-label rusfertide	phase 3	Erythropoietin receptor agonist	Erythropoietin receptor	Nephrology

Therapeutic area mix

Nephrology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dong-A ST Co., Ltd. · 1 shared drug class
Ministry of Health, Malaysia · 1 shared drug class
Sandoz · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Protagonist Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Protagonist Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/protagonist-therapeutics-inc. Accessed 2026-05-16.